Work

Abstract 4736: Dose optimization of olaparib plus temozolomide in small cell lung cancer (SCLC) patient-derived xenograft (PDX) models for clinical translation

Year: 2019

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2019-4736

Authors: Benjamin J. Drapkin, Sarah Phat, David T. Myers, Jun Zhong, Beow Y. Yeap, Elisabetta Leo, Anna Stansiszewska, Aaron Smith, Elaine Cadogan, Maria C. Pietanza, Nicholas J. Dyson, Anna Farago

Institutions: Massachusetts General Hospital, AstraZeneca (United Kingdom), Merck & Co., Inc., Rahway, NJ, USA (United States)

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4255358765

Cites:

Cited by:

Related to: 10